Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Allogene's new CEO Zachary Roberts outlined a strategic refocus on leveraging the intrinsic advantages of allogeneic (off-the-shelf) CAR-T — ready availability, consistent product quality, and ability ...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the ...

Allora's price outlook hinges on adoption versus token unlocks in a volatile AI-crypto niche. Adoption vs. Unlocks – Only ~20% of the 1B ALLO supply circulates, with major backer unlocks extending to ...

The chatter on ALLO is a mix of cautious optimism and technical skepticism. Here’s what’s trending: Traders are watching key support and resistance levels after a volatile breakout, wary of a bull ...

Big Bullish move in ALLO Hello Traders! Allousdt has broken final support and next support is way too much low. So its now planning to use final support to form a reversal pattern and it is heading ...

Ready to watch 'Allo 'Allo!? This 1984 Comedy/War & Politics series is available to watch right now. It's currently streaming on Amazon Prime Video, Peacock Premium, BritBox, Peacock Premium Plus, ...

What is the next earnings date for ALLO stock? ALLOGENE THERAPEUTICS INC (ALLO) will report earnings on 2026-11-04. What are the consensus estimates for ALLOGENE THERAPEUTICS INC (ALLO) next earnings?